• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Policy, Organisation and…
  • Quality of Life

Capturing the Broader Value of Antibiotics

STEDI Roadmap
Read more
  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Innovation for Health System Efficiency and Improvement

Report picture
Read more
  • Drug Development/R&D
  • Value, Affordability, and…
  • Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

6
Read more
  • Antimicrobial Resistance (AMR)
  • Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Proposal for a Novel Antimicrobial  Subscription
Read more
  • Health Care Systems
  • Policy, Organisation and…
  • Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Prev web
Read more
  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 9th April 2018

Valuing Health at the End of Life: A Review of Stated Preference Studies in the Social Sciences Literature

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium. A source of debate in the health care priority setting literature is whether to weight health gains…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Table-for-end-of-life-blog-image-002

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

A source of debate in the health care priority setting literature is whether to weight health gains to account for equity considerations, such as concern for those with very short life expectancy. This issue is particularly pertinent in England, where since 2009 NICE has adopted a supplementary policy in its technology appraisal programme that effectively applies a premium for life-extending end of life treatments. Public preferences have been cited as a rationale for this policy, but until now no published literature review has been available examining the extent of societal support for an end of life premium.
 
In a new paper, just out in Social Science & Medicine, we review 23 empirical studies that sought – either directly or indirectly – to understand people’s preferences regarding the value of end of life treatments. Earlier versions of the review were presented at a seminar at Erasmus University Rotterdam and at the Pharmaccess Leaders Forum. We recently updated the review to capture studies published until October 2017.
 
The evidence is mixed overall, with eight studies that report evidence consistent with a premium for end of life treatments and 11 studies that do not. The remaining studies were considered to have reported mixed or inconclusive evidence. While the number of studies included is insufficient to permit meaningful testing of statistical associations, it appears that the findings of studies may be influenced by methodological and design choices (see table).
 

An open access version of the review is currently available for free download. Click here to access the paper (free access ends on 7 May 2018).
 
Cite as: Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2018. Valuing health at the end of life: A review of stated preference studies in the social sciences literature. Social Science & Medicine, 204, pp.39-50.
 
The review is the latest output from a long-standing research collaboration between OHE and Professors Aki Tsuchiya and Allan Wailoo from the University of Sheffield’s School of Health and Related Research. Related publications include:
  • Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2015. Valuing health at the end of life: A stated preference discrete choice experiment. Social Science & Medicine, 124, pp.48-56. [available open access here]
  • Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2014. Valuing health at the end of life: an empirical study of public preferences. European Journal of Health Economics, 15(4), pp.389-399. [available here]
  • Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2011. Valuing health at the end of life: an exploratory preference elicitation study. OHE Research Paper. London: Office of Health Economics. [available open access here]
The findings from a further study examining the impact of framing effects and study design considerations on end of life-related preferences were presented at the meeting of the International Academy of Health Preference Research in November 2017. A full write-up will be published later this year.
 
  • Health Technology Assessment…
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!